L-Carnitine

Overview

L-Carnitine is a small quaternary ammonium compound, not a peptide, synthesised endogenously from lysine and methionine and also obtained from dietary sources, principally red meat. Its established biochemical role is in the carnitine shuttle, the mechanism by which long-chain fatty acids are transported across the inner mitochondrial membrane for beta-oxidation. Because this role is well characterised and non-controversial, L-carnitine occupies an unusual position among research compounds: the biochemistry is settled, while the question of whether supplementation produces measurable functional effects in people who are not deficient remains actively contested in the published trial literature, with both positive and null randomised results.

For research use only · Not FDA/EMA approved · Not for human consumption

Mechanism of Action

Published biochemistry describes L-carnitine as an obligatory cofactor in the carnitine shuttle. Carnitine palmitoyltransferase I esterifies long-chain fatty acyl-CoA to acylcarnitine on the outer mitochondrial membrane; carnitine-acylcarnitine translocase transports the acylcarnitine across the inner membrane; carnitine palmitoyltransferase II regenerates acyl-CoA within the matrix for beta-oxidation. Published work also describes a buffering role for the free carnitine pool in modulating the mitochondrial acetyl-CoA to CoA ratio. In the exercise literature, proposed mechanisms for supplementation effects include altered substrate utilisation and effects on markers of muscle damage, though the published trials do not agree on whether these translate to performance outcomes.

For research use only · Not FDA/EMA approved · Not for human consumption

Key Research Areas

• Exercise recovery and markers of muscle damage in randomised trials
• Aerobic and anaerobic performance outcomes, including null findings
• Fatigue and exercise capacity in haemodialysis patients
• The carnitine shuttle and mitochondrial fatty acid oxidation
• Clinical carnitine deficiency states

For research use only · Not FDA/EMA approved · Not for human consumption

Published Studies (4 cited)

For research use only · Not FDA/EMA approved · Not for human consumption

Dosage in Published Research

Published human trials have most commonly used oral doses in the range of approximately 1 g to 4 g per day, frequently as L-carnitine L-tartrate in the exercise literature, over supplementation periods of several weeks. Intravenous protocols in the haemodialysis literature use different dosing tied to dialysis sessions. Protocols vary substantially by population and formulation. All figures are reported from published clinical literature for reference purposes only.

For research use only · Not FDA/EMA approved · Not for human consumption

Storage & Handling

Store the solid at room temperature or refrigerated, protected from moisture. L-carnitine is markedly hygroscopic and will absorb atmospheric water, so containers should be kept tightly sealed and equilibrated to room temperature before opening to avoid condensation. Aqueous solutions should be refrigerated and used promptly. Handle under laboratory conditions using appropriate PPE.

For research use only · Not FDA/EMA approved · Not for human consumption

Safety Profile (Literature Only)

Published trial literature describes oral L-carnitine as generally well tolerated at the doses studied, with gastrointestinal effects and a characteristic body odour at higher intakes among the reported effects. A separate published research question concerns the conversion of carnitine by gut microbiota to trimethylamine-N-oxide (TMAO) and the proposed relevance of TMAO to cardiovascular risk; this remains an active area of published debate rather than a settled finding. This compound is supplied for laboratory research use only.

For research use only · Not FDA/EMA approved · Not for human consumption